Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neurocrine Biosciences

120.56
-2.4000-1.95%
Pre-market: 120.560.00000.00%04:08 EDT
Volume:964.82K
Turnover:116.58M
Market Cap:11.93B
PE:40.77
High:122.42
Open:122.42
Low:119.79
Close:122.96
Loading ...
Apr 12, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 11, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 08, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 05, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 04, 2021

Major Issues Report

8-K - Current report
Feb 02, 2021

Major Issues Report

8-K - Current report
Jan 29, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 08, 2021

Major Issues Report

8-K - Current report
Nov 24, 2020

Major Issues Report

8-K - Current report
Nov 19, 2020

Major Issues Report

8-K - Current report
Nov 09, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 09, 2020

Major Issues Report

8-K - Current report
Sep 10, 2020

Major Issues Report

8-K - Current report
Aug 28, 2020

Major Issues Report

8-K - Current report
Aug 03, 2020

Employee Stock Ownership

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Aug 03, 2020

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Aug 03, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]